Candesartan cilexetil in cardiovascular disease

References

• American Heart Association. Heart disease and stroke statistics — 2003 update. American Heart Association TX, USA (2002).
   Google Scholar
• Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood pressure. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute (NHLBI) — National Institutes of Health (3)5233 (2003).
   Google Scholar
• Psaty BM, Furberg CD, Kuller LH et al. Association between blood pressure level and the risk of myocardial infarction, stroke and total mortality: the cardiovascular health study. Arch. Intern. Med. 161,1183–1192 (2001)
   PubMed Web of Science ®Google Scholar
• Vakili BA, Okin PM, Devereux RB. Prognostic implications of left ventricular hypertrophy. Am. Heart. J. 141,334–341 (2001).
   PubMed Web of Science ®Google Scholar
• Coresh J, Wei GL, McQuillan G et al. Prevalence of high blood pressure and elevated serum creatinine level in the USA: findings from the third National Health and Nutrition Examination Survey (1988-1994). Arch. Intern. Med. 161,1207–1216 (2001).
   PubMed Web of Science ®Google Scholar
• Wilson PW. Established risk factors and coronary artery disease: the Framingham Study. Am. J Hypertens. 7(7 Pt 2), S7—S12 (1994).
   Google Scholar
• Hajar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the USA, 1988-2000. J Am. Med. Assoc. 290, 199–206 (2003).
   Web of Science ®Google Scholar
• Stroth U, Unger T. The renin—angiotensin system and its receptors. J Cardiovasc. PharmacoL 33\(Suppl. 1) 521—S28 (1999).
   PubMedGoogle Scholar
• Black H. Evolving role of aldosterone blockers alone and in combination with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in hypertension management: a review of mechanistic and clinical data. Am. Heart J 147(4), 564–572 (2004).
   PubMed Web of Science ®Google Scholar
• Burnier M. Angiotensin II Type 1 receptor blockers. Circulation 103(6), 904–912 (2001).
   PubMed Web of Science ®Google Scholar
• Reif M, White,W, Fagan T et al. Effects of candesartan cilexetil in patients with systemic hypertension. Am. Cardiol. 82(8), 961–965 (1998).
   PubMed Web of Science ®Google Scholar
• Bakris G. Antihypertensive efficacy of candesartan in comparison to losartan: the CLAIM study. J. Clin. Hypertens. 3(1), 16–21 (2001).
   Google Scholar
• Belz G, Butzer R, Kober S, Mutschler E. Pharmacodynamic studies on the angiotensin II type 1 antagonists irbesartan and candesartan based on angiotensin II dose response in humans. J Cardiovasc. PharmacoL 39(4), 561–568 (2002).
   PubMed Web of Science ®Google Scholar
• Contreras F, Cabrera J, Ospino N, Israili Z, Velasco M. Role of angiotensin II AT1 receptor blockers in the treatment of arterial hypertension. Am. J. Therapeut. 10(6), 401–408, (2003).
   PubMedGoogle Scholar
• Sever P. Clinical profile of the novel angiotensin II Type I blacker candesartan cilexetil. j Hypertens. 15\(Suppl. 6), S9—S12 (1997).
   Google Scholar
• Kloner RA, Weinberger M, Poole JL et al. Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Am. J. CardioL 87,727–731 (2001).
   PubMed Web of Science ®Google Scholar
• Eguchi K. Comparison of candesartan with lisinopril on ambulatory blood pressure and morning surge in patients with systemic hypertension. Am. Cardiol. 92(5), 621–624 (2003).
   PubMed Web of Science ®Google Scholar
• Andersson O, Neldam S. Candesartan cilexetil 16 mg provides greater antihypertensive effect than losartan 50 mg in patients with mild-to-moderate hypertension. Am. J Hypertens. 9\(Suppl. 1), 55 (2000).
   PubMedGoogle Scholar
• Papademetriou V, Reif M, Henry D et al Combination therapy with candesartan cilexetil and hydrochlorothiazide in patients with systemic hypertension. J Clin. Hypertens. 2(6), 372–378 (2000).
   Google Scholar
• Papademetriou V, Narayan P, Kikkinos Angiotenin-converting enzyme and angiotensin receptor blockers in hypertensive African Americans. J. Clin. Hypertens. 6,310–314 (2004).
   PubMedGoogle Scholar
• Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial, CHARM-Added, CHARM-preserved. Lancet 362 (9386), 767–781 (2003).
   PubMed Web of Science ®Google Scholar
• Jacobsen P, Rossing K, Parving HH. Single versus dual blockade of the renin—angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy. Curr. Opin. NephroL Hypertens. 13(3), 319–324, (2004).
   PubMed Web of Science ®Google Scholar
• Mogensen CE, Neldam S, Tikkanen I et al, for the CALM study group. Randomized controlled trial of dual blockade of renin—angiotensin system in patients with hypertension, microalbuminuria, and noninsulin-dependent diabetes: the Candesartan And Lisinopril Microalbuminuria (CALM) study. Br. Med. J. 321,1440–1444 (2000).
   PubMed Web of Science ®Google Scholar
• Omoto K, Tanabe K, Tokumoto T, Shimmura H, Ishida H, Tama H. Use of candesartan cilexetil decreases proteinuria in renal transplant patients with chronic allograft dysfunction. Transplantation 76(8), 1170–1174 (2003).
   PubMed Web of Science ®Google Scholar
• Grassi G, Seravalle G, Dell'Oro R et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens. 21(9), 1761–1769 (2003).
   PubMed Web of Science ®Google Scholar
• Lithell H, Hansson L, Skoog I et al., for the SCOPE Study Group. The Study on COgnition and Prognosis in the Elderly (SCOPE): principal results of a randomized, double-blind, intervention trial. J Hypertens. 21 (5), 875–886 (2003).
   PubMed Web of Science ®Google Scholar
• Schrader J, Luders S, Kulschewsk A et al,, on behalf of the ACCESS Study Group. The ACCESS study: evaluation of Acute Candesartan Cilexetil thErapy in Stroke Survivors. Stroke34(7), 1699–1703 (2003).
   Google Scholar
• Kondo J, Sone T, Tsuboi H. Effects of low- dose angiotensin II receptor blacker candesartan on cardiovascular events in patients with coronary artery disease. Am. HeartJ 146(6), E20 (2003).
   PubMedGoogle Scholar
• Ram C, Fenves A. Clinical pharmacology of antihypertensive drugs. Cardiol. Clin. 20(2), 265–280 (2002).
   PubMedGoogle Scholar
• Bakris G, Gradman A, Reif M et al. Antihypertensive efficacy of candesartan in comparison to losartan: the CLAIM study. J Hypertens. 3(1), 16–21 (2001).
   Google Scholar
• Vauquelin G, Fierens FL, De Backer JP, Vanderheyden PM.The effects of candesartan on human AT1 receptor-expressing Chinese hamster ovary cells. J. Am. Soc. Nephrol. 10 (Suppl 11), S15-517 (1999).
   Google Scholar
• Papademetriou V, Farsang C, Elmfeldt D et al. Stroke prevention with the angiotensin II type 1-receptor blacker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J. Am. Coll. Cardial. 44(6), 1175–1180 (2004).
   PubMed Web of Science ®Google Scholar